Articles On ImpediMed (ASX:IPD)

The ASX saw a shaky rally on Monday, mimicking US futures. The ASX 200 gained 6.8 points to 6962. An Australian bank boss has warned the nation to brace for higher banking costs and a potential financial crisis. ANZ Chief Executive Sh...

Benchmark set to finish close to flat as Energy stocks slump again Goldies are surging again, with that sector up 1.3% for the day Even the big banks are bracing for trouble with talk of a crisis getting louder by the day   After a modera...

The Impedimed Limited (ASX: IPD) share price has had a sensational start to the week. In afternoon trade, the ASX biotech share is up 86% to 11 cents. Why is this ASX biotech share rocketing higher? Investors have been buying this ASX biot...

Impedimed (IPD) shares soar on Monday after the US National Comprehensive Cancer Network (NCCN) recommends regular screenings with bioimpedance spectroscopy This marks the first time the NCCN’s Clinical Practice Guidelines in Oncology fo...

ShareCafeEnergy only sector lagging: ASX up 0.27% at noon by Peter Milios   At noon, the S&P/ASX 200 is 0.27 per cent higher at 6,974.10, with all sectors rising except for Energy. The early boost was attributed to US futures rising 0.6...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] A screening platform developed by ImpediMed (ASX: IPD) for the assessment of lymphoedema is expected to increase its profile with the announcement that bioimpedance sp...

ImpediMed surges as the US NCCN included bioimpedance spectroscopy (BIS) as part new guidelines ImpediMed has the only FDA-cleared BIS technology for the assessment of lymphoedema GTG adds 3 new diseases to its geneType Multi-Test   Imped...

ShareCafeStocks of the Hour: IPD, ALO, GBR                    ImpediMed (ASX:IPD) announced that the National Comprehensive Cancer Network® (NCCN®) released a new version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guid...

27 Mar 2023 - A snapshot of the stocks on the move featuring ImpediMed (ASX:IPD), Alloggio Group (ASX:ALO) and Great Boulder Resources (ASX:GBR).

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX health stocks fall 1.87% in the past five days as reporting season ends Healius moves to a statutory loss of ~$29 million following reduced demand for Covid-19 testing Catalysts in next few months for several ASX health stocks which co...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ALG)) - Ardent Leisure ((ASB)) - Austal ((AFG)) - Australian Finance Group ((AVH)) - Avita Medical ((BRI)) - Big River Industries ((SQ2)) - Block ((BXB)) - Brambles ((CB...

These three S&P/ASX All Ords (ASX: XAO) shares are having a mixed day on the market after the release of their latest results today. Helia Group is the standout of these ASX All Ords shares after the company announced a big lift in ea...

ASX health stocks rise 2.27% this week after finishing up 3.9% in January in strong start to 2023 Mach 7 posts a record quarter in sales after landing its largest ever contract in December EBR System’s pivotal trial into WiSE on schedule,...

ShareCafeIron ore surge not enough to lift the ASX: Aus shares close 0.16% lower by Peter Milios   Iron ore prices have reached a seven-month high due to increased demand expectations from China after its reopening following a Covid-19 surg...

ShareCafeASX down 0.15% at noon despite spike in US markets by Peter Milios   The global race for lithium, a commodity crucial for the electric vehicle (EV) industry, has intensified as German Chancellor Olaf Scholz signed an agreement with...

ImpediMed (IPD) appoints Richard Valencia as its Managing Director and CEO, effective December 1Current interim CEO David Anderson will continue to support the company to help ensure a smooth transition of leadershipMr Valencia has 30 years...

Sonic has taken a stake in Microba Immutep enters into second deal with Merck (Germany) and Pfizer  ImpediMed has a new CEO   Sonic takes strategic stake in Microba Giant healthcare stock Sonic Healthcare (ASX:SHL) has bought a stake in s...

ShareCafeASX ignores prospect of further COVID restrictions in China, closes 0.59% higher by Peter Milios   China has reported its first COVID death in six months, sparking up the likelihood of harsher lockdowns. Interestingly, the ASX has...

ShareCafeEyes await the new BNPL laws: ASX up 0.57% at noon by Peter Milios   The Treasury is expected to release a discussion paper today on the BNPL sector. The paper is likely to outline that Australia’s current buy now, pay later provid...

Bod Australia returns positive results from Phase 1 trial Paradigm and Impedimed make executive changes Creso Pharma no longer the subject of ASIC investigation Cannabis stock Bod Australia (ASX:BOD) announced positive results from its Ph...

ASX health stocks extend weekly gains on Friday as markets rally on back of promising US inflation figures Wound care company Avita rises 24% and biotech Antisense is up 18% for past five days Fertility company Monash IVF provides solid H1...

ImpediMed (IPD) extends its clinical trial contract with AstraZeneca for the third timeThe contract is for further use of IPD’s SOZO digital health platform in a clinical trial being conducted by AstraZeneca on chronic kidney diseaseThe tri...

Pharmaxis completes $10 million capital raise, announces positive interim results for Phase II cancer trial Telix price soars on strong Q1 FY23 results including strong sales of its Illuccix product in US market Impedimed Q1 results in lin...

During latest period of volatility many health stocks have seen their share prices remain quite stable Several ASX health stocks have rallied this week on positive news including Polynovo on $5 million sales month Telix Pharmaceuticals ral...

ShareCafeStocks of the Hour: IPD, EFE, VRC                    ImpediMed (ASX:IPD) this morning announced the signing of a Global Strategic Commercial Partnership and pilot program with GenesisCare. The pilot program will consist of an...

04 Oct 2022 - A snapshot of the stocks on the move featuring ImpediMed (ASX:IPD), Eastern Resources (ASX:EFE) and Volt Resources (ASX:VRC).

Paradigm successfully meets primary endpoint of Phase 2 trial Immutep granted Fast Track designation by the FDA ImpediMed signs strategic partnership with GenesisCare Paradigm Biopharma (ASX:PAR) surged 19% this morning after announcing t...

Monday was not the start to the week that investors were probably hoping for. By the time the closing bell belted out its chime, the S&P/ASX All Ords Index (ASX: XAO) had taken a 2% beating to the downside. Not even the release of ear...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. The health sector falls sligh...

Medical software technology company ImpediMed (ASX:IPD) has announced the departure of its managing director and CEO Richard Carreon.

ImpediMed’s (IPD) Managing Director and CEO, Richard Carreon, resigns after a decade with the company Effective by close of business today, Mr Carreon will step down, saying it is the right time to do so with the company “operationally sou...

ImpediMed (IPD) publishes a paper on the risk factors for breast cancer related lymphoedema Key findings of the paper include support for the use of a prospective surveillance model of care, and identifies patients who may benefit from mor...

The ASX will open firmer on Monday  Wall Street little changed on Friday despite strong US non-farms data This week we will see US CPI and China’s GDP data released Local blue chips will open firmer today, with the July ASX 200 futures po...

Gold aspirant Cavalier Resources announces its new substantial shareholders following IPO Gold stocks in demand as investors seek the traditional inflationary hedge Hard hit health and e-commerce stocks continue to lose substantial shareho...

Nordic Nickel announces its new substantial shareholders following its June 2 debut Sigma Healthcare defies ASX health stocks to keep rising and attract new substantial shareholders Hard-hit e-commerce and health stocks among those to lose...

ASX healthcare stocks finish the week modestly in the green Lumos and Audeara rattle the tin in a bid to raise more capital EOFY sell downs puts more pressure on ailing health stocks Healthcare and life sciences expert Scott Power, who ha...

Healthcare and life sciences expert Scott Power – a senior analyst with Morgans Financial for 24 years – on what the movers and shakers have been doing in health and which ASX health stocks make Scott’s Powerplays. Look in the mirror and li...

ImpediMed (IPD) has welcomed a second contract extension and expansion of its SOZO Digital Health Platform for use in clinical trials being conducted for AstraZeneca The phase two trial will use the SOZO devices to track patient fluid volu...

In this week’s ScoPo’s Powerplays, healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, examines the turbulent start to 2022 for ASX health stocks and what could lie ahead as ge...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. First a note on things are are...

At the time of writing, the ASX 200 Health Index (XHJ) is down 2%, while the benchmark ASX 200 is also falling by 0.75%. The path is now open for pharma distributor Australian Pharmaceutical Industries (ASX: API) to be acquired by Wesfarmer...

ImpediMed (IPD) announces clinical trial agreement for its SOZO platform, which helps patients with end stage renal disease by assisting with removing fluid during dialysis The company has entered into the agreement with Balboa Research a...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Everyone loves a comeback. Just...

ImpediMed (IPD) sees its PREVENT Trial results peer-reviewed and published ImpediMed’s study demonstrated intervention in patients with early detection of cancer-related lymphoedema using its L-Dex technology can result in a lower rate of...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week It’s been a...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

Highlights The rising population and the rise in health issues are increasing the demand for healthcare products and services. People’s lifestyle is one of the reasons for rising health issues in the present times. TLX, RHT, CYC, IPD,...

ImpediMed (IPD) completes its share purchase plan, heavily oversubscribed by more than $27 million The share purchase plan (SPP) closed on November 12 and saw applications totalling over $32 million – well in excess of the company’s target...